Conmed Stock CNMD
ConMed Corporation is a medical device company that develops, manufactures, and markets surgical products for use by healthcare professionals across two reporting segments. Conmed stock (CNMD): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 07/2026, quarterly reporting. Stock analysis by NadirAlpha. Conmed stock (CNMD): listed on NYSE. NadirAlpha has evaluated 46 original documents, cross-checked every figure automatically and linked each to its source; sources as of 07/2026. Revenue Q2 2026: USD 344 million (+0% year on year). Latest reported (Q2 2026): Gore distribution agreement termination benefit, Common stock repurchases, Write-off of deferred financing fees. Latest reading: Guidance confirmed, Partnership, Revenue accelerating.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Conmed Current Status
Summary of the most recent reporting period of Conmed (Q2 2026): core figures, drivers and management statements, every figure with a source number. NadirAlpha methodology
Assessment by NadirAlpha, as of Q2 2026.
“We are updating our financial guidance for the full year 2026 today to reflect both our second quarter performance and our updated outlook for the balance of the year. Looking ahead, our team remains focused on disciplined execution as we continue to position CONMED for quality, long-term growth and value creation.”
“We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations. Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace. In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team.”
Conmed Stock: Key Figures ($ million)
Revenue, margin, earnings and EPS of Conmed per fiscal year, half-year and quarter in $ million, as of Q2 2026, as reported in the filing; restatements show the most recent filing version. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | OCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 1,374.7 | 102.6 | – | 47.1 | 1.51 | 4.59 | 275.89 | 170.7 | 27 |
| FY2024 | 1,307 | 200.3 | 202.78 | 132.4 | 4.25 | 4.17 | 265.57 | 167 | 19 |
| FY2023 | 1,244.7 | 120.6 | 174.39 | 64.5 | 2.04 | 3.45~ | 235.45 | 125.3 | 10 |
Quarters
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-07-29 | 343.5 | 36.4 | – | 23.1~ | 0.77 | 1.38 | 78.1 | – | 37.3 | 619.7 | 30 |
| 2026-Q1* | 2026-04-29 | 317 | 25.4 | 41.5 | 13.8 | 0.44*≈ | 0.89 | 56.4 | – | – | – | 28 |
| 2025-Q4* | 2026-01-28 | 373.2 | 36.6 | – | 16.7 | 0.54*≈ | 1.43 | 80.4 | 41.2 | 40.8 | 793.4 | 26 |
| 2025-Q3* | 2025-11-05 | 337.9 | 11.9 | – | 2.9 | 0.09 | 1.08 | 65.6 | 48.5 | 38.9 | 814.1 | 24 |
| 2025-Q2* | 2025-07-30 | 342.3 | 38.2 | – | 21.4 | 0.69 | 1.15 | 68.6 | 23.4 | 33.9 | 847.2 | 22 |
| 2025-Q1* | 2025-04-30 | 321.3 | 16 | 45.3 | 6 | 0.19 | 0.95 | 61.3 | 37.8 | 35.5 | 856 | 120 |
| 2024-Q4* | 2025-02-05 | 345.9 | 52.5 | 64.5 | 33.8 | 1.08*≈ | 1.34 | 80 | 39.3 | 24.5 | 880.6 | 118 |
| 2024-Q3* | 2024-10-04 | 316.7 | 65.7 | – | 49 | 1.57 | 1.05 | 64.6 | 47.8 | 38.5 | 901.6 | 15 |
| 2024-Q2* | 2024-07-31 | 332.1 | 47.1 | – | 30 | 0.96 | 0.98 | 64.6 | 39.7 | 28.9 | 936.3 | 113 |
| 2024-Q1* | 2024-04-24 | 312.3 | 35 | – | 19.7 | 0.63 | 0.66~ | 56.3 | 27.1 | 33.9 | 956.3 | 111 |
| 2023-Q4* | 2024-01-31 | 327 | 50.2 | 51.8 | 33.1 | 1.05*≈ | 0.42~ | 66.9 | 51.5 | 24.3 | 948.8 | 109 |
| 2023-Q3* | 2023-10-25 | 304.6 | 30.3 | – | 15.8 | 0.50 | 0.77~ | 59.7 | 40.7 | 30.5 | 911.7 | 107 |
| 2023-Q2* | 2023-07-26 | 317.7 | 27.4 | – | 13.7 | 0.43 | 0.76~ | 57.6 | 22.1 | 27.8 | 943.6 | 105 |
| 2023-Q1* | 2023-04-26 | 295.5 | 12.7 | – | 1.8 | 0.06 | 0.66 | 51.2 | -8.1 | 26.5 | 968.8 | 103 |
Conmed Balance Sheet & Cash Flow ($ million)
NadirAlpha places cash, debt, operating cash flow and investments of Conmed side by side per period, balance sheet values as of the period end, flow items for the period. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-01-28 | 40.8 | 834.2 | 793.4 | 52.3 | 170.7 | 19.8 | 150.9 | 26 |
| FY2024 | 2025-02-05 | 24.5 | 905.1 | 880.6 | 51.3 | 167 | 13.1 | 153.9 | 118 |
| FY2023 | 2024-01-31 | 24.3 | 973.1 | 948.8 | 51.4 | 125.3 | 19 | 106.3 | 109 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-07-29 | 37.3 | 657 | 619.7 | – | – | – | – | 30 |
| 2025-Q4 | 2026-01-28 | 40.8 | 834.2 | 793.4 | 13.2 | 46.3 | 5.1 | 41.2 | 26 |
| 2025-Q3 | 2025-11-05 | 38.9 | 853 | 814.1 | 13.2 | 53.7 | 5.2 | 48.5 | 24 |
| 2025-Q2 | 2025-07-30 | 33.9 | 881.1 | 847.2 | 13.1 | 29.1 | 5.7 | 23.4 | 22 |
| 2025-Q1 | 2025-04-30 | 35.5 | 891.4 | 856 | 12.9 | 41.5 | 3.8 | 37.8 | 120 |
| 2024-Q4 | 2025-02-05 | 24.5 | 905.1 | 880.6 | 12.9 | 43.3 | 4 | 39.3 | 118 |
| 2024-Q3 | 2024-10-30 | 38.5 | 940.1 | 901.6 | 13 | 51.2 | 3.4 | 47.8 | 16 |
| 2024-Q2 | 2024-07-31 | 28.9 | 965.2 | 936.3 | 12.8 | 43.3 | 3.6 | 39.7 | 113 |
| 2024-Q1 | 2024-04-24 | 33.9 | 990.1 | 956.3 | 12.6 | 29.1 | 2 | 27.1 | 111 |
| 2023-Q4 | 2024-01-31 | 24.3 | 973.1 | 948.8 | 13 | 56.4 | 4.9 | 51.5 | 109 |
| 2023-Q3 | 2023-10-25 | 30.5 | 942.2 | 911.7 | 12.6 | 46.1 | 5.4 | 40.7 | 107 |
| 2023-Q2 | 2023-07-26 | 27.8 | 971.5 | 943.6 | 13 | 26.7 | 4.5 | 22.1 | 105 |
| 2023-Q1 | 2023-04-26 | 26.5 | 995.3 | 968.8 | 12.9 | -3.8 | 4.3 | -8.1 | 103 |
Conmed Guidance Tracking (latest per metric/period · 9/15)
All forecasts (guidance) of the Conmed management and their later outcome: per metric and period the most recent statement applies, the status is checked against the reported actuals. NadirAlpha methodology
Actuals: revenue in $m · EPS in $ per share · ratios in %
Direction: confirmedcutinitiatedraised Verdict: beatin linemisspending
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-07-29 | Revenue | 1,358–1,373 | – | 31 | ||
| FY2026 | 2026-07-29 | EPS (non-GAAP) | 4.48–4.6 | – | 31 | ||
| FY2026 | 2026-07-29 | Net Sales Growth, As Reported | -1.2–-0.1% | – | 31 | ||
| FY2026 | 2026-07-29 | Net Sales Growth, Constant Currency | -1.7–-0.7% | – | 31 | ||
| FY2026 | 2026-07-29 | Net Sales Growth, Organic Constant Currency | 5–6% | – | 31 | ||
| FY2026 | 2026-04-29 | Gastroenterology Product Sales | 14.5–17.5 | – | 28 | ||
| FY2026 | 2026-01-28 | Organic Constant Currency Growth | 4.5–6% | – | 26 | ||
| FY2025 | 2025-11-05 | Revenue | 1,365–1,372 | 1,374.7 | 24 | ||
| FY2025 | 2025-11-05 | EPS (non-GAAP) | 4.48–4.53 | 4.59 | 24 | ||
| FY2024 | 2024-10-30 | Revenue | 1,300–1,305 | 1,307 | 16 | ||
| FY2024 | 2024-10-30 | EPS (non-GAAP) | 4–4.05 | 4.17 | 16 | ||
| 2024-Q3 | 2024-10-04 ° | Revenue | 315–318 | 316.7 | 15 | ||
| 2024-Q3 | 2024-10-04 ° | EPS (non-GAAP) | 9–11% | 1.05 | 15 | ||
| FY2023 | 2023-10-25 | Revenue | 1,240–1,260 | 1,244.7 | 7 | ||
| FY2023 | 2023-10-25 | EPS (non-GAAP) | 3.45–3.55 | – | – | 7 |
Conmed Stock: Price & Chart
Interactive price chart of Conmed stock (TradingView) and the trend of key figures from the core tables; the chart loads only after a click and then connects to TradingView. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Conmed Event Timeline
NadirAlpha sorts 57 events of Conmed by quarter, most recent first, each with source number and event type, management quotes as direct quotes at the start of the quarter. NadirAlpha methodology
2026 · 7 events
Q2 net sales increased 0.3% as reported, recovering from Q1 decline; orthopedic surgery advanced 8.2% and organic constant currency growth excluding GI exits was 6.0% 31
Full-year 2026 guidance updated to net sales $1,358-$1,373 million, organic constant currency growth 5.0%-6.0%, and adjusted diluted EPS $4.48-$4.60 31
AirSeal Robotic Solution received indication for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform, expanding the scope of the Intuitive collaboration 31
“Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations. We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
Gross profit margin improved to 57.9% from 55.3% in Q1 2026, driven by the Gore distribution termination benefit, favorable foreign currency impact, and product mix 29
CONMED exited gastroenterology product lines, including termination of Gore VIABIL biliary stent distribution effective January 1, 2026, as part of portfolio optimization 29
Full-year 2026 organic constant currency revenue growth guidance raised to 5.0%-6.5% from prior 4.5%-6.0%; reported revenue guidance raised to $1.350-$1.375 billion 28
2025 · 18 events
“Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives. As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long‑term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
Company announced December 5, 2025 intent to exit gastroenterology product lines; accelerated termination of Gore VIABIL biliary stent distribution agreement to January 1, 2026 as part of portfolio optimization strategy 27
Q4 net sales +7.9% YoY (+7.1% constant currency) to $373.2M; international revenue +17.0% as reported and +15.4% in constant currency; full-year 2025 revenue +5.2% to $1,374.7M 26
2026 full-year guidance initiated: revenue $1.345-$1.375B (4.5%-6% organic constant currency growth); adjusted diluted EPS $4.30-$4.45 including approximately $0.10 currency tailwind 26
“We are pleased with our third quarter performance, which reflects continued progress in strengthening our supply chain and strong execution across our core growth platforms. We are building on this momentum in the fourth quarter and beyond, supported by our portfolio of best-in-class clinical solutions, operational discipline, and commitment to innovation.”
Gross profit margin declined 730bps to 49.2% in Q3, driven by $19.7M in inventory write-offs for cancelled product lines and tariff costs 25
Q3 net sales +6.7% YoY (+6.3% constant currency) to $337.9M; domestic +5.9%, international +7.8% as reported 24
Board authorized $150M share repurchase program and suspended quarterly cash dividend; company anticipates repurchasing at least $25M in shares annually beginning in 2026 24
Operating income more than halved YoY (65.7 to USD 11.9 million, -82%). 24
“We are encouraged by our second quarter performance as we focused on building a stronger operational foundation. We continue to strengthen our supply chain operations with a focus on turning this into an area of strength within CONMED. We remain very confident in the long-term potential of our four key growth drivers and the solid foundation for sustained revenue and earnings growth that they provide.”
Gross profit margin declined 30bps to 55.0% due to consulting charges for supply chain and manufacturing improvements and inventory write-offs, partially offset by favorable product mix 23
Q2 net sales +3.1% YoY to $342.3M; Single-use Products segment +6.6%, Capital Products revenue -15.5% 22
Full-year adjusted diluted EPS guidance raised to $4.40-$4.55 from prior $4.31-$4.46; revenue range narrowed to $1.356-$1.378B with foreign currency headwinds now expected to be immaterial 22
“We had a good start to 2025, which positions us well to achieve our full-year guidance. I am proud of our team's dedication to strengthening our operations in order to better support our key growth platforms and drive long-term shareholder value.”
GAAP diluted EPS fell to $0.19 from $0.63 in Q1 2024; S&A expenses rose 680bps to 46.3% of sales, driven by $12.2M in CEO advisory compensation and $10.5M net contingent consideration fair value expense, not operational deterioration 21
Q1 net sales +2.9% YoY (+3.8% constant currency) to $321.3M; domestic +4.2%, international +1.2% as reported, with growth across orthopedic and general surgery product lines 20
Full-year revenue guidance raised to $1.350-$1.378B from $1.344-$1.372B; adjusted diluted EPS guidance raised to $4.45-$4.60 from $4.25-$4.40; FX headwind revised to 50-70bps from 100-120bps 20
Operating income more than halved YoY (35.0 to USD 16.0 million, -54%). 120
2024 · 19 events
“2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability. In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.”
Q4 adjusted diluted EPS increased 26.4% to $1.34; full-year adjusted diluted EPS rose 20.9% to $4.17 and adjusted EBITDA grew to $265.6 million from $235.4 million in 2023 18
Q4 net sales increased 5.8% year-over-year to $345.9 million (6.0% constant currency), re-accelerating from the 4.0% growth rate in Q3 2024; Single-use Products segment grew 9.6% in Q4 18
“Our third quarter results were largely in line with our expectations, and we remain focused on getting fully back on offense. I am particularly proud of how our teams responded to the disruption from hurricanes Helene and Milton, which temporarily impacted our employees and facilities in the Southeast as well as many of our customers.”
Gross profit margin expanded 130 basis points to 56.5% in Q3 2024, primarily due to favorable product mix 17
Full-year adjusted diluted EPS guidance raised to $4.00-$4.05 from prior range of $3.95-$4.02, while full-year revenue guidance was modestly reduced to $1.300-$1.305 billion 16
COO Patrick Beyer announced as successor to President and CEO Curt Hartman, effective January 1, 2025, upon Mr. Hartman's retirement 16
Operating income more than doubled YoY (30.3 to USD 65.7 million, +117%). 16
“Our second quarter and first half of 2024 played out largely as expected. Looking forward, we have not yet fully recovered from our supply chain challenges, which has delayed the commercial reacceleration that we had contemplated in our plan at the beginning of the year. We remain highly focused on getting back on offense to serve our customers and driving above-market, long-term growth.”
Q2 net sales increased 4.5% year-over-year to $332.1 million (5.2% constant currency), decelerating from the 5.7% growth rate in Q1 2024 13
Gross profit margin improved 160 basis points to 55.3% in Q2 2024, due to favorable product mix and the absence of In2Bones inventory step-up amortization costs that were present in the prior-year period 13 14
Full-year revenue guidance cut to $1.305-$1.315 billion and adjusted diluted EPS guidance reduced to $3.95-$4.02, as supply chain challenges delayed previously anticipated commercial reacceleration 13
Net income more than doubled YoY (13.7 to USD 30.0 million, +119%). 113
“2024 is off to a solid start as the quarter delivered our expected top- and bottom-line growth and margin expansion. We remain well positioned with a compelling and diverse portfolio to drive continued growth across the markets we serve.”
Q1 net sales increased 5.7% year-over-year to $312.3 million (5.9% constant currency), led by growth in orthopedic surgery and general surgery product lines 11
Gross profit margin expanded 250 basis points to 55.1% from 52.6% in Q1 2023, driven by favorable product mix 11 12
Full-year revenue guidance lowered to $1.330-$1.355 billion and adjusted diluted EPS guidance reduced to $4.25-$4.35, citing approximately $10 million in incremental foreign currency headwinds 11
Operating income more than doubled YoY (12.7 to USD 35.0 million, +176%). 111
2023 · 13 events
“2023 was a great year for CONMED, and I am proud that our global business delivered record revenue in both the fourth quarter and for the full year. The balanced growth we saw across our various businesses and geographies is a testament to the strength of the portfolio that we have built. As we shift our focus to 2024, we are very excited to continue delivering innovative technology solutions to our customers and patients across both the General Surgery and Orthopedics categories.”
Full-year 2023 net income of $64.5M vs. net loss of $80.6M in 2022; full-year adjusted diluted EPS increased 30.2% to $3.45 9
Q4 net sales of $327.0M grew 30.4% YoY; full-year net sales reached $1,244.7M, up 19.1% as reported and 20.9% in constant currency 9
“The third quarter saw our team drive double-digit revenue and earnings growth amid healthy end markets. I'm proud of what we've accomplished year to date in 2023, particularly that the team has been able to drive above-market revenue growth in both businesses.”
Quarterly gross margin expanded 10 bps to 55.2%, first YoY quarterly improvement in FY2023, as warehouse management system disruptions abated 8
Net sales grew 10.7% YoY to $304.6M, further decelerating; acquisitions contributed ~40 bps; nine-month revenue up 15.5% 7
Full-year 2023 revenue guidance lower end raised to $1.240B–$1.260B; adjusted diluted EPS lower end raised to $3.45 to $3.55 7
“Our team drove excellent growth across both Orthopedics and General Surgery during the second quarter, building on the momentum we generated during the first three months of the year. We remain confident in our ability to grow above market and continue to deliver clinical innovation to our customers.”
Gross margin fell 110 bps to 53.7% in Q2, driven by inflation in raw materials, freight, and production costs 6
Net sales grew 14.6% YoY to $317.7M, decelerating from 21.9% in Q1; acquisitions contributed ~400 bps 5
Full-year 2023 revenue guidance raised to $1.230B–$1.260B; adjusted diluted EPS guidance raised to $3.40 to $3.55 5
“I am proud of our team for driving excellent first quarter results and staying focused on serving our customers. Our strong first quarter provides a very solid start to the year, and the team is focused on execution and delivering on our increased outlook.”
Gross margin fell 350 bps to 52.6% due to inflation and acquisition-related inventory step-up costs 4
Net sales grew 21.9% YoY to $295.5M; In2Bones and Biorez acquisitions contributed ~570 bps of growth 3
Full-year 2023 revenue guidance raised to $1.205B–$1.250B; adjusted diluted EPS guidance raised to $3.30 to $3.50 3
Conmed Business Model
The Conmed business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology
ConMed Corporation is a medical device company that develops, manufactures, and markets surgical products for use by healthcare professionals across two reporting segments. The orthopedic surgery segment encompasses sports medicine devices, powered instruments, and related capital equipment, while the general surgery segment centers on advanced energy devices, insufflation systems including the AirSeal platform, and related surgical tools; the company exited its gastroenterology product line in 2025-2026 as part of a portfolio optimization strategy. Revenue is generated through direct sales to hospitals and ambulatory surgery centers in the United States and through a combination of direct sales forces and distributor networks in international markets, with capital equipment placements typically followed by recurring consumable and single-use device purchases.
Conmed Stock: Share-Price Drivers
Factors Conmed itself names as material for its business development, reproduced neutrally, without price forecast and without assessment of our own. NadirAlpha methodology
Growth is described as accelerating with guidance raised and profitability improving, while quarterly revenue reached USD 343.5 million and net debt was reduced to USD 619.7 million 31 30
Orthopedic Surgery revenue up 6.8% year-on-year, supported by In2Bones, Biorez and BioBrace product growth 29 17
AirSeal Robotic Solution gained an indication for the Intuitive da Vinci 5, expanding its addressable use, though the reported General Surgery segment revenue was lower 31 29
International revenue up 4.7% year-on-year while Domestic revenue was lower 28
Capital Products revenue up 4.6% year-on-year 29
Strategic exits of gastroenterology product offerings and termination of the Gore VIABIL biliary distribution agreement remove revenue from the base 31 30 28
Repurchase of $645.2 million principal amount of 2.250% Convertible Notes, with net debt reduced to USD 619.7 million from higher prior-quarter levels 30 31
Sector trend: Medical-device demand across orthopedic, robotic surgery and international channels is trending higher, while single-use and domestic gastroenterology-related lines are being wound down; adjusted profitability improved with adjusted EPS of 1.38 31 29.
Conmed Revenue by Type (as of 2026-Q2 · USD million · 6/6)
Where the revenue of Conmed comes from: segments and product types with share, growth and margin, as of Q2 2026, older structures remain in the expandable part. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Source |
|---|---|---|---|---|
| Period 2026-Q1 (3M) | ||||
| Single-use Products | 2023-Q1 | 270 | -2.3% | 29 |
| Domestic | 2023-Q1 | 173 | -5.8% | 28 |
| General Surgery | 2023-Q1 | 169.3 | -7.4% | 29 |
| Orthopedic Surgery | 2023-Q1 | 147.7 | 6.8% | 29 |
| International | 2023-Q1 | 144 | 4.7% | 28 |
| Capital Products | 2023-Q1 | 47 | 4.6% | 29 |
Conmed Products & announcements (2/5 active+recent)
Product announcements of Conmed from the reports: market launches, approvals, partnerships, with first mention and source; discontinued products are shown in grey. NadirAlpha methodology
Status: Launched
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2026 | |||
| AirSeal Robotic Solution indication for Intuitive da Vinci 5 | 2026-07 | 31 | |
| Manufacturing and supply agreement for gastroenterology products | 2026-06 | 30 | |
| 2024 | |||
| Biliary product expansion | 2024-09 | 17 | |
| BioBrace product growth (4×) | 2024-06 | 17 | |
| 2023 | |||
| Warehouse management system implementation | 2023 | 8 | |
Conmed Transactions & Events (13)
All recorded acquisitions, divestitures and exits of Conmed, plus partnerships, contracts and regulatory events affecting the business, each with date and source. NadirAlpha methodology
Acquisitions by Conmed
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Biorez acquisition contingent consideration payments | 2026-06 | Completed | 30 |
| 2024 | |||
| Buffalo Filter acquisition | 2024 | Completed | 19 |
| 2022 | |||
| In2Bones acquisition (2×) | 2022 | Completed | 17 |
| Biorez acquisition | 2022 | Completed | 19 |
Divestitures and exits by Conmed
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Sale of additional gastroenterology assets recorded as business sale in Q2 2026 | 2026-06 | Divested | 30 |
| Sale of certain gastroenterology assets | 2026-04 | Divested | 29 |
| Sale of gastroenterology assets in Q1 2026 | 2026-03 | Divested | 30 |
| Divestiture of remaining gastroenterology portfolio | 2026-03 | Divested | 28 |
| 2025 | |||
| Gastroenterology product line exit (5×) | 2025-12 | Divested | 27 |
| Sale of product line | 2025-03 | Divested | 20 |
| Product line discontinuations and cancellations | 2025 | Divested | 27 |
Partnerships and contracts of Conmed
Conmed Risks (82 since the annual report of 2026-02-17, 149 tracked in total)
NadirAlpha lists 82 active risks of Conmed from the filings, the category as a coloured dot with legend, the wording as a short summary of the filing with no assessment of our own. NadirAlpha methodology
Category: StrategyCustomersRegulatoryGeopoliticsMacroFinancialTechnologyLegalSupply chainCyberPeopleCompetitionMarket
| Risk | Category | Last reported |
|---|---|---|
| Conmed: first mention in 8-K-EX99.1 earnings release of 2026-07-29 (2026-Q2), source 31 | ||
| Gastroenterology product line strategic exits affect comparability | = | |
| Domestic sales decreased 8.0% as reported in Q2 2026 | = | |
| Conmed: first mention in 10-Q quarterly report of 2026-07-29 (2026-Q2), source 30 | ||
| Environmental compliance risks including lack of availability of EtO sterilization | = | |
| EU Medical Device Regulations (MDR) compliance costs incurred | 2026-Q2 2026-07-29 31 | |
| Trade protection measures, tariffs and border taxes impacting operations | = | |
| No material impact from Ukraine and Middle East conflicts but continued monitoring required | = | |
| Impact of pandemics and health crises on operations | = | |
| Conmed: first mention in 10-Q quarterly report of 2024-10-31 (2024-Q3), source 17 | ||
| Effects of inflation and increased interest rates on operating costs | 2026-Q2 2026-07-29 30 | |
| Failure or disruption of enterprise-wide software and IT systems | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-Q quarterly report of 2024-04-25 (2024-Q1), source 12 | ||
| Risk of patent, product and other litigation including associated costs | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-K annual report of 2024-02-28 (FY2023), source 10 | ||
| Cyclical customer purchasing patterns due to budgetary and staffing constraints | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-Q quarterly report of 2023-10-26 (2023-Q3), source 8 | ||
| Ongoing supply chain challenges and constraints in availability and cost of materials | 2026-Q2 2026-07-29 30 | |
| Ability to defend and enforce intellectual property in international operations | 2026-Q2 2026-07-29 30 | |
| Potential enforcement actions by regulatory agencies against company or distributors | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-Q quarterly report of 2023-07-27 (2023-Q2), source 6 | ||
| Risk of information security breach including cybersecurity threats | 2026-Q2 2026-07-29 30 | |
| General economic and business conditions including potential economic downturn | 2026-Q2 2026-07-29 30 | |
| Ability to attract, motivate and retain employees at all levels | 2026-Q2 2026-07-29 30 | |
| Changes in customer preferences affecting product demand | 2026-Q2 2026-07-29 30 | |
| Challenges and uncertainties in product research and development | 2026-Q2 2026-07-29 30 | |
| Competitive pressures in medical device market | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-Q quarterly report of 2023-04-27 (2023-Q1), source 4 | ||
| Risk of lack of allograft tissues due to reduced donations or screening failures | 2026-Q2 2026-07-29 30 | |
| Conmed: first mention in 10-Q quarterly report of 2026-04-30 (2026-Q1), source 29 | ||
| General economic downturn, supply chain challenges, inflation, and interest rate increases | = | |
| Impact of divestitures of products or product portfolios | = | |
| Failure of enterprise software/IT systems or cybersecurity breaches | = | |
| Conmed: first mention in 8-K-EX99.1 earnings release of 2026-04-29 (2026-Q1), source 28 | ||
| Higher-than-previously anticipated interest expense from planned debt refinancing in 2026. | = | |
| Exit of certain gastroenterology products reduced net sales and impacted domestic revenue. | = | |
| Potential issues with certain royalty payments to design surgeons identified in 2025. | = | |
| Company incurred costs to comply with European Union Medical Device Regulations (MDR). | = | |
| Company focusing investment on higher-growth and higher-margin minimally invasive surgery areas. | = | |
| Conmed: first mention in 10-K annual report of 2026-02-17 (FY2025), source 27 | ||
| Conversion of 2.250% Convertible Notes due 2027 could require substantial cash payments or reduce working capital | = | |
| $800 million 2.250% Convertible Notes due June 15, 2027; company seeking incremental financing with no assurance. | = | |
| $840 million debt outstanding represents 44% of capitalization; inability to service could require alternative strategies affecting growth | = | |
| High leverage limits financial flexibility, reduces ability to pursue acquisitions and make capital investments | = | |
| Variable rate borrowings expose Company to interest rate risk which could increase debt service obligations and reduce cash flows | = | |
| Extended product supply disruptions risk losing customers permanently despite eventual supply resumption. | = | |
| Changes in surgeon preferences, healthcare spending and customer purchasing patterns could reduce product demand | = | |
| Cost reduction efforts in healthcare industry including GPO/IDN purchasing arrangements create pricing and margin pressures | = | |
| Climate change expected to increase frequency/severity of adverse weather; business interruption insurance capped/limited. | = | |
| Third-party payors declining or reducing reimbursement could reduce demand for products and create pricing pressure | = | |
| Rapid technological change could render products obsolete if Company fails to develop competitive new products and technologies | = | |
| Loss of distribution rights to third-party products such as Gore VIABIL could negatively impact business | = | |
| Competition for qualified personnel in medical industry; inability to attract/retain could adversely affect performance. | = | |
| $61.4 million contingent consideration obligations from acquisitions with timing/payment uncertainty. | = | |
| Evolving ESG laws/regulations require investments; non-compliance risks fines, product sale prohibitions, reputation damage. | = | |
| Failure to comply with FDA QSR and regulatory requirements could result in recalls, fines, product seizures, import restrictions, suspension of manufacturing | = | |
| Deployment of AI and emerging technologies could result in deficient content, competitive disadvantage or regulatory non-compliance | = | |
| Board may suspend/eliminate dividend payments; senior credit agreement restricts dividend payments. | = | |
| Foreign operations subject to currency conversion restrictions, withholding taxes, trade barriers, political instability. | = | |
| Anti-takeover provisions and Delaware law may delay/prevent shareholder-favorable acquisitions. | = | |
| FCPA and anti-bribery laws impose obligations on international operations; non-compliance could result in criminal and civil penalties | = | |
| GDPR imposes fines up to 4% of global revenue; CCPA, CPRA and other state privacy laws require compliance across multiple jurisdictions | = | |
| Anti-Kickback Statute and other healthcare laws constrain business arrangements; violations could result in civil, criminal and administrative penalties | = | |
| HIPAA business associate requirements could result in criminal or civil sanctions for non-compliance with protected health information rules | = | |
| Conmed: first mention in 10-Q quarterly report of 2025-07-31 (2025-Q2), source 23 | ||
| Pandemics and health crises and government/hospital responses | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 8-K-EX99.1 earnings release of 2025-07-30 (2025-Q2), source 22 | ||
| Company incurring costs for third party services pertaining to potential issues with royalty payments to surgeons involved in design teams. | = | |
| Conmed: first mention in 10-Q quarterly report of 2025-05-01 (2025-Q1), source 21 | ||
| Higher manufacturing/operating costs from inflationary pressures and tariffs on imported goods impacting results. | FY2025 2026-02-17 27 | |
| Conmed: first mention in 8-K-EX99.1 earnings release of 2025-04-30 (2025-Q1), source 20 | ||
| Costs incurred for third party services pertaining to potential issues with certain royalty payments to surgeons. | = | |
| Conmed: first mention in 10-K annual report of 2025-02-18 (FY2024), source 19 | ||
| Higher manufacturing costs may require further cost reduction or debt refinancing if mitigation efforts fail. | FY2025 2026-02-17 27 | |
| Manufacturing/supplier facilities vulnerable to hurricanes, earthquakes, fires, pandemics; Hurricane Milton impacted Florida facility. | FY2025 2026-02-17 27 | |
| Company could face patent infringement claims or lose patent protection which could reduce competitive advantage | FY2025 2026-02-17 27 | |
| Approximately 31% of products sterilized using EtO; further restrictions on capacity or government actions could materially impact ability to transition to alternatives | FY2025 2026-02-17 27 | |
| Highly competitive market with large competitors could reduce revenues through competitive pricing pressures or new product introductions | FY2025 2026-02-17 27 | |
| Conmed: first mention in 10-Q quarterly report of 2024-10-31 (2024-Q3), source 17 | ||
| Current and future levels of indebtedness and capital spending | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 10-Q quarterly report of 2024-08-01 (2024-Q2), source 14 | ||
| Introduction and acceptance of new products in market | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 10-Q quarterly report of 2024-04-25 (2024-Q1), source 12 | ||
| Ability to defend and enforce intellectual property in international operations | 2026-Q1 2026-04-30 29 | |
| Trade protection measures, tariffs, border taxes, and import/export licensing requirements | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 10-K annual report of 2024-02-28 (FY2023), source 10 | ||
| Limited supply of allograft tissue donors and MTF performance constraints could limit ability to increase service fees | FY2025 2026-02-17 27 | |
| Medical device nature of products creates exposure to product liability claims; insurance coverage may be insufficient | FY2025 2026-02-17 27 | |
| Raw material shortages, inflation, price increases, tariffs and geopolitical developments could increase operating costs | FY2025 2026-02-17 27 | |
| Federal False Claims Act and state equivalents prohibit false claims for government payment; violations could result in substantial fines and exclusion from programs | FY2025 2026-02-17 27 | |
| Conmed: first mention in 10-Q quarterly report of 2023-10-26 (2023-Q3), source 8 | ||
| Risk of patent, product and other litigation and associated costs | 2025-Q2 2025-07-31 23 | |
| Changes in technology | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 10-Q quarterly report of 2023-07-27 (2023-Q2), source 6 | ||
| Environmental compliance risks including EtO sterilization availability | 2026-Q1 2026-04-30 29 | |
| Failure of key IT systems, software programs or disruptions from system updates could materially impact business operations | FY2025 2026-02-17 27 | |
| Availability, terms and deployment of capital | 2026-Q1 2026-04-30 29 | |
| Changes in foreign exchange and interest rates | 2026-Q1 2026-04-30 29 | |
| Weather related events that may disrupt operations | 2026-Q1 2026-04-30 29 | |
| Compliance with and changes in laws and regulatory requirements | 2026-Q1 2026-04-30 29 | |
| Ability to evaluate, finance and integrate acquired businesses | 2026-Q1 2026-04-30 29 | |
| Changes in business strategy | 2026-Q1 2026-04-30 29 | |
| Cyclical customer purchasing patterns due to budgetary and staffing constraints | 2026-Q1 2026-04-30 29 | |
| Conmed: first mention in 10-Q quarterly report of 2023-04-27 (2023-Q1), source 4 | ||
| Risk of patent, product and other litigation and associated costs | 2026-Q1 2026-04-30 29 | |
Conmed Reported KPIs (as disclosed) (377)
NadirAlpha collects 377 reported KPIs of Conmed from the filings up to Q2 2026; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| Conmed, published 2026-07-29, period 2026-Q2 | ||
| Write-off of deferred financing fees | $3.5 | 30 |
| Weighted average interest rate | 2.84% | 30 |
| Weighted average interest rate | 2.80% | 30 |
| Weighted average interest rate | 2.80% | 30 |
| Weighted average interest rate | 2.85% | 30 |
| Variable rate debt sensitivity (1% change, quarterly interest impact) | $1.7 | 30 |
| Total variable rate debt | $683.0 | 30 |
| Term A-2 Loan outstanding | $450.0 | 30 |
| Term A-2 Loan borrowings | $450.0 | 30 |
| Term A-1 Loan outstanding | $40.0 | 30 |
| Share repurchase authorization | $150.0 | 30 |
| Revolving credit facility borrowings | $193.0 | 30 |
| Revenue from single-use products | 86% | 30 |
| Remaining 2.250% Convertible Notes | $154.8 | 30 |
| Professional fees related to note repurchase | $1.8 | 30 |
| Planned 2026 share repurchases | $61.8 | 30 |
| Outstanding letters of credit | $1.5 | 30 |
| Operational optimization consulting and legal fees | $7.1 | 30 |
| Operational optimization consulting and legal fees | $2.5 | 30 |
| Operational optimization consulting and legal fees | $14.6 | 30 |
| Operational optimization consulting and legal fees | $2.9 | 30 |
| Operating cash flow | $50.6 | 30 |
| Operating cash flow | $70.7 | 30 |
| Net working capital | $220.3 | 30 |
| Net gain on sale of gastroenterology assets | $1.5 | 30 |
| Net borrowings on revolving credit facility | $193.0 | 30 |
| Manufacturing and supply agreement duration (gastroenterology) | twelve months | 30 |
| Loss on sale of gastroenterology assets | $4.4 | 30 |
| International sales percentage | 47% | 30 |
| International sales percentage | 44% | 30 |
| Income from note repurchase | $8.1 | 30 |
| IEEPA tariff refunds received | $10.2 | 30 |
| Gore distribution agreement termination benefit | $1.9 | 30 |
| Gastroenterology sales | $4.7 | 30 |
| Gastroenterology sales | $25.3 | 30 |
| Gastroenterology sales | $14.1 | 30 |
| Gastroenterology sales | $50.3 | 30 |
| Gain on sale of product offering | $1.9 | 30 |
| Gain on sale of product offering | $5.9 | 30 |
| Gain on extinguishment of 2.250% Notes | $4.6 | 30 |
| Effective tax rate | 26.4% | 30 |
| Effective tax rate | 28.4% | 30 |
| Effective tax rate | 25.8% | 30 |
| Effective tax rate | 27.0% | 30 |
| EU Medical Device Regulations compliance costs | $1.1 | 30 |
| EU Medical Device Regulations compliance costs | $2.3 | 30 |
| Dividends paid | $12.4 | 30 |
| Contingent consideration | $28.9 | 30 |
| Contingent consideration | $14.1 | 30 |
| Consulting engagement charge | $5.1 | 30 |
| Consulting engagement charge | $8.5 | 30 |
| Common stock repurchases | $43.2 | 30 |
| Common stock repurchased (shares) | 1.0 | 30 |
| Common stock repurchased (aggregate value incl. excise tax) | $43.7 | 30 |
| Cash used in financing activities | $68.8 | 30 |
| Cash used in financing activities | $54.9 | 30 |
| Cash proceeds from sale of gastroenterology assets | $21.5 | 30 |
| Capital expenditures | $5.8 | 30 |
| Capital expenditures | $9.5 | 30 |
| Available borrowings on revolving credit facility | $455.5 | 30 |
| Annual minimum share repurchases | $25.0 | 30 |
| Advisory services compensation (former CFO) | $3.3 | 30 |
| Advisory services compensation (former CEO | $12.2 | 30 |
| Adjusted EBITDA Margin | 22.7% | 31 |
| Adjusted EBITDA Margin | 20.0% | 31 |
| Adjusted EBITDA Margin | 20.4% | 31 |
| Adjusted EBITDA Margin | 19.6% | 31 |
| 2.250% Notes repurchased (principal) | $645.2 | 30 |
| 2.250% Notes repurchase (cash consideration) | $637.2 | 30 |
| 2.250% Convertible Notes maturity date | June 15, 2027 | 30 |
| 2.250% Convertible Notes issued | $800.0 | 30 |
| Conmed, published 2026-04-30, period 2026-Q1 | ||
| Weighted average interest rate | 2.62% | 29 |
| Total shares repurchased under program | 0.9 million shares | 29 |
| Total amount repurchased under program | $37.4 | 29 |
| Term loan borrowings outstanding | $40.0 | 29 |
| Single-use products sales | $270.0 | 29 |
| Selling and administrative expense | $141.7 | 29 |
| Revolving credit facility borrowings outstanding | $25.0 | 29 |
| Research and development expense | $16.3 | 29 |
| Planned share repurchases for | $61.8 | 29 |
| Outstanding convertible notes principal | $800.0 | 29 |
| Orthopedic surgery sales | $147.7 | 29 |
| Orthopedic surgery percentage of sales | 47% | 29 |
| Net working capital | $377.9 | 29 |
| Net sales | $317.0 | 29 |
| Net cash used in financing activities | -$22.6 | 29 |
| Net cash provided by operating activities | $13.5 | 29 |
| Net borrowings on revolving line of credit | $25.0 | 29 |
| Letters of credit set aside | $1.6 | 29 |
| International sales percentage | 45% | 29 |
| Interest expense | $7.1 | 29 |
| Income from operations | $25.4 | 29 |
| Income before income taxes | $18.3 | 29 |
| Gross profit margin | 57.9% | 29 |
| General surgery sales | $169.3 | 29 |
| General surgery percentage of sales | 53% | 29 |
| Gastroenterology sales | $9.5 | 29 |
| Effective tax rate | 24.7% | 29 |
| Convertible notes interest rate | 2.250% | 29 |
| Contingent consideration paid - Biorez | $11.4 | 29 |
| Common stock repurchases | $37.0 | 29 |
| Capital products sales | $47.0 | 29 |
| Capital expenditures | $2.9 | 29 |
| Available borrowings on revolving credit facility | $623.4 | 29 |
| Annual share repurchase target | $25.0 | 29 |
| Conmed, published 2026-04-29, period 2026-Q1 | ||
| Operating Income Margin (reported) | 8.0% | 28 |
| Operating Income Margin (adjusted) | 13.1% | 28 |
| Gross Profit Margin (reported) | 57.9% | 28 |
| Gross Profit Margin (adjusted) | 57.4% | 28 |
| Effective Tax Rate (reported) | 24.7% | 28 |
| Effective Tax Rate (adjusted) | 24.2% | 28 |
| EBITDA Margin | 14.0% | 28 |
| Adjusted EBITDA Margin | 17.8% | 28 |
| Conmed, published 2026-02-17, period FY2025 | ||
| Weighted average interest rate on borrowings | 2.79% | 27 |
| Weighted average interest rate on borrowings | 3.15% | 27 |
| Total cash | 40.8 | 27 |
| Term loan facility borrowings | 40.0 | 27 |
| Stock-based compensation expense | 28.3 | 27 |
| Stock-based compensation expense | 25.6 | 27 |
| Stock-based compensation expense | 24.3 | 27 |
| Single-use products % of revenues | 86% | 27 |
| Shares repurchased under Prior Program | 6.1 | 27 |
| Shares repurchased amount | 162.6 | 27 |
| Sales in local currency % | 32% | 27 |
| Orthopedic surgery % | 42% | 27 |
| Operational optimization consulting fees | 12.9 | 27 |
| Net working capital | 357.8 | 27 |
| Modified repurchase program | 150.0 | 27 |
| International sales % | 44% | 27 |
| Interest rate sensitivity | 0.4 | 27 |
| Gore distribution agreement termination benefit | 9.9 | 27 |
| General surgery % | 58% | 27 |
| Former CEO compensation and advisory services | 12.2 | 27 |
| Foreign subsidiaries cash | 29.3 | 27 |
| Foreign currency exchange positive impact | 1.9 | 27 |
| Export basis sales in USD % | 12% | 27 |
| Effective tax rate | 33.8% | 27 |
| Effective tax rate | 18.8% | 27 |
| Contingent consideration - In2Bones | 2.2 | 27 |
| Contingent consideration - Biorez | 59.2 | 27 |
| Consultant engagement costs | 12.5 | 27 |
| Available borrowings on revolving credit facility | 648.5 | 27 |
| 2.250% Convertible Notes due | 800.0 | 27 |
| Conmed, published 2026-01-28, period 2025-Q4 | ||
| EBITDA Margin | 14.9% | 26 |
| EBITDA Margin | 20.4% | 26 |
| EBITDA Margin | 12.8% | 26 |
| EBITDA Margin | 20.8% | 26 |
| Adjusted EBITDA Margin | 21.5% | 26 |
| Adjusted EBITDA Margin | 23.1% | 26 |
| Adjusted EBITDA Margin | 20.1% | 26 |
| Adjusted EBITDA Margin | 20.3% | 26 |
| Conmed, published 2025-11-06, period 2025-Q3 | ||
| Single-use products % of revenue | approximately 86% | 25 |
| Operating cash flow | $124.4 million | 25 |
| Net working capital | $347.5 million | 25 |
| International sales percentage | 43% | 25 |
| Gore VIABIL gross profit margin | approximately 38% | 25 |
| Gore VIABIL distribution revenue | $44.1 million | 25 |
| Capital expenditures | $14.7 million | 25 |
| Available borrowings on revolving credit facility | $648.5 million | 25 |
| Conmed, published 2025-11-05, period 2025-Q3 | ||
| Adjusted operating income % | 15.1 (USD %) | 24 |
| Adjusted EBITDA Margin | 19.4 | 24 |
| Conmed, published 2025-07-31, period 2025-Q2 | ||
| Working capital | 362.9 | 23 |
| Term loan outstanding | 85.0 | 23 |
| Revolving credit borrowings | 4.0 | 23 |
| Operating cash flow | 70.7 | 23 |
| Capital expenditures | 9.5 | 23 |
| Available revolving credit | 644.4 | 23 |
| Conmed, published 2025-05-01, period 2025-Q1 | ||
| Weighted average interest rate | 2.90 % | 21 |
| Single-use products % of revenue | 86 % | 21 |
| Shares repurchased through March 31 | 6.1 million | 21 |
| Share repurchase program authorized | 200.0 million | 21 |
| Remaining available for share repurchases | 37.4 million | 21 |
| Orthopedic surgery product line percentage | 43 % | 21 |
| Net working capital | 355.9 million | 21 |
| International sales percentage | 43 % | 21 |
| Gross profit margin | 55.3 % | 21 |
| General surgery product line percentage | 57 % | 21 |
| Effective tax rate | 21.3 % | 21 |
| Available borrowings on revolving credit facility | 583.4 million | 21 |
| Amount repurchased through March 31 | 162.6 million | 21 |
| Conmed, published 2025-04-30, period 2025-Q1 | ||
| Operating Income Margin | 5.0% | 20 |
| Gross Profit Margin | 55.3% | 20 |
| Effective Tax Rate | 21.3% | 20 |
| EBITDA Margin | 10.6% | 20 |
| Adjusted Operating Income Margin | 14.1% | 20 |
| Adjusted Gross Profit Margin | 56.4% | 20 |
| Adjusted Effective Tax Rate | 23.1% | 20 |
| Adjusted EBITDA Margin | 19.1% | 20 |
| Conmed, published 2025-02-18, period FY2024 | ||
| Total debt outstanding | $914.6 million | 19 |
| Single-use products % of revenues | 85% | 19 |
| Royalty expense | $6.8 million | 19 |
| Royalty expense | $5.3 million | 19 |
| Royalty expense | $3.2 million | 19 |
| Research and development | $54.4 million | 19 |
| Research and development | $52.6 million | 19 |
| Research and development | $47.2 million | 19 |
| Orthopedic surgery single-use products percentage | 77% | 19 |
| Orthopedic surgery revenue percentage | 42% | 19 |
| Orthopedic surgery percentage | 43% | 19 |
| Orthopedic surgery percentage | 44% | 19 |
| International sales percentage | 43% | 19 |
| International sales percentage | 44% | 19 |
| International sales percentage | 45% | 19 |
| International sales local currency percentage | 32% | 19 |
| International sales export basis USD percentage | 11% | 19 |
| General surgery single-use products percentage | 91% | 19 |
| General surgery revenue percentage | 58% | 19 |
| General surgery percentage | 57% | 19 |
| General surgery percentage | 56% | 19 |
| EtO sterilized products percentage | 31% | 19 |
| Employees in operations | 2,400 | 19 |
| Debt as percentage of total capitalization | 48% | 19 |
| Capital products percentage of revenues | 15% | 19 |
| Availability under senior credit agreement | $583.4 million | 19 |
| Conmed, published 2025-02-05, period 2024-Q4 | ||
| Operating Income Margin | 15.2% | 18 |
| Operating Income Margin | 15.3% | 18 |
| Operating Income Margin | 15.3% | 18 |
| Operating Income Margin | 9.7% | 18 |
| Gross Profit Margin | 57.3% | 18 |
| Gross Profit Margin | 55.7% | 18 |
| Gross Profit Margin | 56.1% | 18 |
| Gross Profit Margin | 54.3% | 18 |
| Effective Tax Rate | 22.7% | 18 |
| Effective Tax Rate | 18.7% | 18 |
| Effective Tax Rate | 18.8% | 18 |
| Effective Tax Rate | 20.3% | 18 |
| EBITDA Margin | 20.4% | 18 |
| EBITDA Margin | 20.9% | 18 |
| EBITDA Margin | 20.8% | 18 |
| EBITDA Margin | 15.5% | 18 |
| Adjusted Operating Income Margin | 18.6% | 18 |
| Adjusted Operating Income Margin | 15.8% | 18 |
| Adjusted Operating Income Margin | 15.5% | 18 |
| Adjusted Operating Income Margin | 14.0% | 18 |
| Adjusted Gross Profit Margin | 57.6% | 18 |
| Adjusted Gross Profit Margin | 56.4% | 18 |
| Adjusted Gross Profit Margin | 56.3% | 18 |
| Adjusted Gross Profit Margin | 55.2% | 18 |
| Adjusted Effective Tax Rate | 26.7% | 18 |
| Adjusted Effective Tax Rate | 24.2% | 18 |
| Adjusted Effective Tax Rate | 24.1% | 18 |
| Adjusted Effective Tax Rate | 23.0% | 18 |
| Adjusted EBITDA Margin | 23.1% | 18 |
| Adjusted EBITDA Margin | 20.5% | 18 |
| Adjusted EBITDA Margin | 20.3% | 18 |
| Adjusted EBITDA Margin | 18.9% | 18 |
| Conmed, published 2024-10-31, period 2024-Q3 | ||
| Weighted average interest rate (3 months) | 3.15% | 17 |
| Weighted average interest rate (9 months) | 3.18% | 17 |
| Term loan facility borrowings | 114.6 million | 17 |
| Single-use products % of sales | 85% | 17 |
| Revolving credit facility borrowings | 36.0 million | 17 |
| Orthopedic surgery sales % | 41% | 17 |
| OCF (9 months) | 123.6 million | 17 |
| Net working capital | 358.7 million | 17 |
| International sales percentage | 43% | 17 |
| General surgery sales % | 59% | 17 |
| Effective tax rate (3 months) | 13.2% | 17 |
| Effective tax rate (9 months) | 17.4% | 17 |
| Available borrowings on revolving credit facility | 547.4 million | 17 |
| Conmed, published 2024-10-30, period 2024-Q3 | ||
| Operating margin | 20.7% | 16 |
| Operating income | 65,707 | 16 |
| Net sales | 316,701 | 16 |
| Gross profit margin | 56.5% | 16 |
| EBITDA Margin | 26.4% | 16 |
| EBITDA | 83,681 | 16 |
| Diluted EPS | 1.57 | 16 |
| Conmed, published 2024-08-01, period 2024-Q2 | ||
| Working capital | 357.4 million | 14 |
| Term loan outstanding | 114.6 million | 14 |
| Single-use products % | 84% | 14 |
| Shares repurchased | 6.1 million | 14 |
| Share repurchase remaining | 37.4 million | 14 |
| Share repurchase completed | 162.6 million | 14 |
| Share repurchase authorization total | 200.0 million | 14 |
| Revolving credit outstanding | 62.0 million | 14 |
| Operating cash flow H1 | 72.4 million | 14 |
| International sales % | 44% | 14 |
| Capex H1 | 5.6 million | 14 |
| Available borrowings | 521.4 million | 14 |
| Conmed, published 2024-04-25, period 2024-Q1 | ||
| Single-use products % of revenues | 85% | 12 |
| Orthopedic surgery % of consolidated net sales | 43% | 12 |
| International sales % of consolidated net sales | 44% | 12 |
| General surgery % of consolidated net sales | 57% | 12 |
| Conmed, published 2024-02-28, period FY2023 | ||
| Weighted average interest rate on borrowings | 3.12% | 10 |
| Variable rate long-term debt | 116.6 million | 10 |
| Term loan borrowings outstanding | 114.6 million | 10 |
| Stock-based compensation expense | 24.3 million | 10 |
| Single-use products overall | 83% | 10 |
| Single-use products - Orthopedic | 76% | 10 |
| Single-use products - General Surgery | 89% | 10 |
| Shares repurchased | 6.1 million | 10 |
| Share repurchase authorization | 200.0 million | 10 |
| Selling and administrative expense as % of net sales | 40.4% | 10 |
| Royalty expense | 5.3 million | 10 |
| Royalty expense | 3.2 million | 10 |
| Royalty expense | 2.0 million | 10 |
| Revolving credit facility borrowings | 2.0 million | 10 |
| Research and development expense as % of net sales | 4.2% | 10 |
| Research and development expense | 52.6 million | 10 |
| Research and development expense | 47.2 million | 10 |
| Research and development expense | 43.6 million | 10 |
| Remaining repurchase authorization | 37.4 million | 10 |
| Operating cash flow | 125.3 million | 10 |
| Net working capital | 304.9 million | 10 |
| International sales percentage | 32% | 10 |
| International sales - percentage of total | 44% | 10 |
| Gross profit margin | 54.3% | 10 |
| Foreign cash held by subsidiaries | 19.7 million | 10 |
| Effective income tax rate | 20.3% | 10 |
| Debt outstanding | 986.6 million | 10 |
| Debt as percentage of total capitalization | 54% | 10 |
| Contingent consideration - In2Bones | 41.4 million | 10 |
| Contingent consideration - Biorez | 128.8 million | 10 |
| Cash on hand | 24.3 million | 10 |
| Capital products | 17% | 10 |
| Available borrowings on revolving credit facility | 581.4 million | 10 |
| Availability under senior credit agreement | 581.4 million | 10 |
| Amount spent on repurchases | 162.6 million | 10 |
| Conmed, published 2023-10-26, period 2023-Q3 | ||
| Weighted average interest rate | 3.17% | 8 |
| Weighted average interest rate | 2.66% | 8 |
| Weighted average interest rate | 3.13% | 8 |
| Weighted average interest rate | 2.44% | 8 |
| Term loan borrowings | 134.6 million | 8 |
| Single-use products % of revenues | 84% | 8 |
| Shares repurchased to date | 6.1 million | 8 |
| Share repurchase program authorization | 200.0 million | 8 |
| Selling and administrative expense as % of sales | 41.1% | 8 |
| Selling and administrative expense as % of sales | 41.7% | 8 |
| Selling and administrative expense as % of sales | 42.0% | 8 |
| Selling and administrative expense as % of sales | 41.9% | 8 |
| Revolving credit facility borrowings | 22.0 million | 8 |
| Research and development expense as % of sales | 4.1% | 8 |
| Research and development expense as % of sales | 4.6% | 8 |
| Research and development expense as % of sales | 4.2% | 8 |
| Research and development expense as % of sales | 4.4% | 8 |
| Remaining available for share repurchases | 37.4 million | 8 |
| Orthopedic surgery percentage of net sales (Q3) | 41% | 8 |
| Orthopedic surgery percentage of net sales (9M) | 43% | 8 |
| Net working capital | 249.3 million | 8 |
| International sales percentage | 44% | 8 |
| International sales percentage | 45% | 8 |
| Gross profit margin | 55.2% | 8 |
| Gross profit margin | 55.1% | 8 |
| Gross profit margin | 53.8% | 8 |
| Gross profit margin | 55.3% | 8 |
| General surgery % of net sales (Q3) | 59% | 8 |
| General surgery % of net sales (9M) | 57% | 8 |
| Available borrowings on revolving credit facility | 561.4 million | 8 |
| Amount spent on share repurchases to date | 162.6 million | 8 |
| Conmed, published 2023-10-25, period 2023-Q3 | ||
| Adjusted EBITDA Margin | 19.6% | 7 |
| Adjusted EBITDA Margin | 18.4% | 7 |
| Conmed, published 2023-07-27, period 2023-Q2 | ||
| Weighted average interest rates | 3.09% | 6 |
| Weighted average interest rates | 3.11% | 6 |
| Term loan borrowings outstanding | 134.6 million | 6 |
| Shares repurchased to date | 6.1 million | 6 |
| Selling and administrative expense | 40.8% | 6 |
| Selling and administrative expense | 42.4% | 6 |
| Revolving credit facility borrowings | 54.0 million | 6 |
| Research and development expense | 4.3% | 6 |
| Research and development expense | 4.3% | 6 |
| Repurchase program remaining | 37.4 million | 6 |
| Repurchase program cost to date | 162.6 million | 6 |
| Net working capital position | 262.4 million | 6 |
| Net cash from operating activities | 22.8 million | 6 |
| Letters of credit | 1.6 million | 6 |
| Interest expense | 3.1% | 6 |
| Interest expense | 3.3% | 6 |
| Income from operations | 8.6% | 6 |
| Income from operations | 6.5% | 6 |
| Gross profit margin | 53.7% | 6 |
| Gross profit margin | 53.2% | 6 |
| Effective tax rate | 21.2% | 6 |
| Effective tax rate | 21.7% | 6 |
| Available borrowings on revolving facility | 529.4 million | 6 |
| Conmed, published 2023-04-26, period 2023-Q1 | ||
| Operating Income Margin | 4.3% | 3 |
| Gross Profit Margin | 52.6% | 3 |
| EBITDA Margin | 10.4% | 3 |
| Adjusted EBITDA Margin | 17.3% | 3 |
Conmed Development
How Conmed has developed since 2023: one paragraph per period on revenue, earnings, cash flow and drivers, most recent period first, grouped by year. NadirAlpha methodology
FY2026: Conmed
CONMED's first half of fiscal 2026 was shaped by the deliberate exit from gastroenterology product lines, which weighed on reported net sales while the orthopedic surgery segment delivered solid underlying growth. Q1 net sales were USD 317 million, down 1.3% as reported and 2.9% in constant currency, with a $15.5 million revenue headwind from the gastroenterology exit; CONMED raised its full-year organic constant currency growth guidance to 5.0%-6.5% following the quarter 28. Q2 net sales reached USD 343.5 million, up 0.3% as reported, as the orthopedic surgery segment advanced 8.2% and organic constant currency growth excluding GI exits was 6.0% 30 31. Gross profit margins expanded across both quarters, reaching 57.9% in Q1 and 57.5% in Q2, driven by the Gore distribution termination benefit and favorable product mix 29 30. In Q2, CONMED repurchased $645.2 million principal of its 2.250% Convertible Notes; adjusted diluted EPS reached 1.38 including a $0.21 IEEPA tariff refund benefit, and net debt stood at USD 619.7 million at period end 30 31.
FY2025: Conmed
CONMED's full-year 2025 net sales rose 5.2% as reported (5.1% in constant currency) to $1,374.7 million, with growth in both orthopedic surgery (5.6%) and general surgery (4.9%) product lines and sequential acceleration from +2.9% in Q1 to +7.9% in Q4 26 27. Full-year adjusted diluted EPS increased to $4.59 from $4.17 in 2024, while GAAP net income fell sharply to $47.1 million from $132.4 million in 2024, as selling and administrative expenses rose to 43.1% of net sales from 36.6%, driven by advisory compensation for the former CEO, a $64.0 million swing in contingent consideration fair value from $41.0 million income in 2024 to $23.0 million expense in 2025, and operational optimization consulting costs 27. Gross profit margin contracted 1.5 percentage points to 54.6%, primarily reflecting $12.5 million in supply chain consulting charges and $22.2 million in inventory write-offs for cancelled product lines 27. Operating cash flow increased slightly to $170.7 million from $167.0 million despite lower net income, supported by favorable working capital timing and lower interest expense as weighted average borrowings and rates declined 27. The Board suspended the quarterly dividend in October 2025, authorized a $150 million share repurchase program, and in December 2025 the company announced its intent to exit gastroenterology product lines, including termination of the Gore VIABIL biliary stent distribution agreement effective January 1, 2026 24 27.
FY2024: Conmed
CONMED reported full-year 2024 net sales of $1,307.0 million, an increase of 5.0% year-over-year as reported and 5.3% in constant currency, with domestic revenue growing 6.9% and international revenue increasing 2.6% as reported, driven by growth in both orthopedic surgery and general surgery product lines 18 19. The Single-use Products segment grew 7.1% for the full year while the Capital Products segment declined 5.5%, with approximately 85% of revenues derived from single-use products 18 19. Full-year gross profit margin expanded 180 basis points to 56.1% primarily due to favorable product mix, adjusted diluted EPS increased 20.9% to $4.17, and adjusted EBITDA rose to $265.6 million from $235.4 million in 2023 18 19. Free cash flow reached $153.9 million and net debt stood at $880.6 million at year-end, with the remaining $70.0 million of 2.625% Notes repaid in February 2024 18 19. Persistent supply chain challenges and hurricane-related manufacturing disruptions were navigated throughout the year, concluding with a planned leadership transition as Patrick Beyer was announced as incoming President and CEO effective January 1, 2025, succeeding retiring CEO Curt Hartman 16 17 18.
FY2023: Conmed
CONMED Corporation reported full-year 2023 net sales of $1,244.7 million, a 19.1% increase from $1,045.5 million in 2022, with acquisitions of In2Bones Global and Biorez contributing approximately 250 basis points of growth 9 10. Conmed returned to profitability with net income of $64.5 million compared to a net loss of $80.6 million in 2022, aided by a reduction in selling and administrative expenses as a percentage of net sales from 43.4% to 40.4% 9 10. Gross margin was 54.3% in 2023, down 0.3 percentage points from 2022, as inflation in raw materials, freight, and production costs offset volume-related gains 10. Operating cash flow improved significantly to $125.3 million from $33.4 million in the prior year, while net debt stood at $948.8 million at year-end 10 18. Revenue growth decelerated from 21.9% in Q1 to 10.7% in Q3 before re-accelerating to 30.4% in Q4, supported by warehouse management system improvements and organic demand across product lines 3 7 9.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
The evidence base for Conmed stock: every document with type and date, every figure in the report leads here by number and to the original by link. NadirAlpha methodology
Older sources (+15)
| # | Document type | Published |
|---|---|---|
| #202 | 10-K annual report | 2016-05-02 |
| #201 | 10-Q quarterly report | 2016-07-28 |
| #204 | 10-K annual report | 2017-02-27 |
| #206 | 10-K annual report | 2017-02-27 |
| #203 | 10-Q quarterly report | 2017-07-27 |
| #205 | 10-Q quarterly report | 2018-08-02 |
| #208 | 10-K annual report | 2019-02-25 |
| #207 | 10-Q quarterly report | 2019-08-01 |
| #212 | 10-K annual report | 2020-02-24 |
| #209 | 10-Q quarterly report | 2020-04-30 |
| #210 | 10-Q quarterly report | 2020-07-30 |
| #211 | 10-Q quarterly report | 2020-10-29 |
| #213 | 10-Q quarterly report | 2021-04-29 |
| #214 | 10-Q quarterly report | 2021-07-29 |
| #215 | 10-Q quarterly report | 2021-10-28 |
Conmed Stock FAQ
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Conmed report?
As reported for Q2 2026: Gore distribution agreement termination benefit, Common stock repurchases, Write-off of deferred financing fees, Weighted average interest rate (three months 2026), Weighted average interest rate (three months 2025), Weighted average interest rate (six months 2026). The chapter Reported KPIs lists every value with its source. Revenue is broken down by Single-use Products, Domestic, General Surgery, Orthopedic Surgery.
Does Conmed pay a dividend?
The filings report on the dividend; most recent entry: dividends paid $12.4 (2026-Q2) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Conmed?
NadirAlpha links all 46 original filings used (SEC filings) in the sources chapter: earnings release, quarterly report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.